Whitehawk Therapeutics (NASDAQ:WHWK) CFO Sells $297,220.00 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CFO Scott Giacobello sold 77,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $3.86, for a total value of $297,220.00. Following the sale, the chief financial officer owned 436,824 shares in the company, valued at approximately $1,686,140.64. The trade was a 14.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Whitehawk Therapeutics Stock Performance

NASDAQ:WHWK opened at $4.11 on Monday. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48. The firm has a market cap of $193.99 million, a price-to-earnings ratio of 8.74 and a beta of 0.57. The business’s fifty day moving average is $3.46 and its 200 day moving average is $2.79.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.21.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Wall Street Zen lowered Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Citigroup assumed coverage on Whitehawk Therapeutics in a research note on Thursday. They set an “outperform” rating on the stock. Oppenheimer began coverage on Whitehawk Therapeutics in a research note on Thursday, February 5th. They set an “outperform” rating and a $6.00 price objective on the stock. Finally, Citizens Jmp began coverage on Whitehawk Therapeutics in a research note on Thursday. They issued a “market outperform” rating and a $8.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Whitehawk Therapeutics News Roundup

Here are the key news stories impacting Whitehawk Therapeutics this week:

• Positive Sentiment: Citizens/JMP initiated coverage with a “Market Outperform” and an $8.00 price target (roughly ~95% above recent levels), a catalyst that has supported buying interest ahead of impending trial data. Citizens Outperform
• Neutral Sentiment: Whitehawk’s CEO will appear in a Jones Trading Post–AACR virtual fireside chat on April 23 — a visibility event that can help inform investors but is unlikely to move the stock by itself. Fireside Chat
• Neutral Sentiment: Institutional ownership is meaningful (~52%) and coverage is mixed: a consensus “Hold” with an average target near $6.50 (some firms bullish, others negative), so analyst views are a mixed influence on price. Institutional Holdings
• Negative Sentiment: Significant insider selling this week — CFO Scott Giacobello sold 141,600 shares (4/16) and 77,000 shares (4/15) and director/officer Bryan Ball sold multiple blocks — has increased supply and likely pressured the stock. Company disclosures say the sales were to cover tax withholding on vested awards, but the size and frequency of sales reduced insiders’ stakes materially. SEC filings: CFO Form 4 and Other Insider Forms

Hedge Funds Weigh In On Whitehawk Therapeutics

A number of institutional investors have recently added to or reduced their stakes in WHWK. Vanguard Group Inc. bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $2,552,000. Peapod Lane Capital LLC bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $577,000. Dimensional Fund Advisors LP bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $84,000. Avoro Capital Advisors LLC bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $5,414,000. Finally, Suvretta Capital Management LLC bought a new position in Whitehawk Therapeutics in the 3rd quarter worth about $7,030,000. 52.08% of the stock is currently owned by institutional investors.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.